Notch Therapeutics

Notch Therapeutics is an immunocyte therapy company that has developed a next-generation product of ready-to-use, universal, genetically modified T-cell therapies derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.Notch has pioneered a next-generation approach to mass produce uniform, stem cell-derived, gene-edited immunotherapies by mimicking the "niche" of the human thymus where T cells originate. At the core of Notch’s technology is the proprietary Engineered Thymic Niche (ETN) platform, which enables the expansion and differentiation of induced pluripotent stem cells (iPSCs) in fully defined, feeder-free, and serum-free cultures into mature T cells and other scalable types of immune cells, creating cell banks for thousands of patients. A key feature of our technology is that immune cells can be uniformly gene-edited at the stem cell stage for any immunotherapy-based therapeutic application, including CAR, CRISPR, and synthetic biology.